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Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders
caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is
associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by
mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell
lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only
genetic abnormalities reported so far in some patients with NL/MGCLS and in one individual with
LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in
PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore
further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established
genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in
BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with
syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study
demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no
obvious genotype–phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway
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represents the common and basic molecular event predisposing to giant cell lesion formation in patients
with NS and CFCS rather than specific mutation effects.
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Introduction
Noonan syndrome (NS; MIM 163950) is an autosomal
dominant developmental disorder characterized by con-
genital heart defects, facial anomalies, short stature,
webbed neck, chest deformity, developmental delay of
variable degree, and cryptorchidism in males.1,2 Several
distinct entities show phenotypic similarities to NS,
including LEOPARD syndrome (LS; MIM 151100), cardio-
facio-cutaneous syndrome (CFCS; MIM 115150), and
Costello syndrome (CS; MIM 218040). This group of
clinically overlapping disorders is caused by mutations in
genes encoding various components of the RAS-MAPK
pathway, which relays signals from activated cell surface
receptors to the nucleus. NS can be caused by mutations in
the genes PTPN11, SOS1, RAF1 or KRAS,3 – 8 whereas CFCS is
associated with mutations in BRAF, MEK1, MEK2 or
KRAS.9,10 HRAS mutations have been identified in the vast
majority of patients with Costello syndrome11,12 and
specific PTPN11 mutations are responsible for LS.13,14
Giant cell lesions (GCL) are benign tumor-like lesions
most frequently affecting the jaws but also occurring in
other bones or soft tissues. They consist of multinucleated
giant cells in a background of fibrous connective tissue
with abundant spindle-shaped mononucleated cells.15 The
pathogenesis of GCL formation is incompletely under-
stood. There is evidence that the mononucleated (osteo-
blast-like) cell population represents proliferating tumor
cells that produce cytokines inducing the maturation of a
subset of mononuclear phagocytes into osteoclast-like
giant cells.15 GCL can be multilocular, and extensive
involvement of the jaws can lead to the clinical picture
of cherubism (MIM 118400), which can be caused by
mutations of SH3BP2,16 a gene encoding for an adapter
protein involved in intracellular signaling in hemato-
poietic and hematopoietic lineage-derived cells.
Multiple giant cell lesions (MGCL) have repeatedly been
observed in patients with clinical features of NS. The term
Noonan-like/MGCL syndrome (NL/MGCLS; MIM 163955)
was coined for this association.17,18 Once thought to be a
separate entity, it is now rather considered a variant of the
NS spectrum.19–22 This notion was supported by the finding
of PTPN11 mutations in a number of patients with
NL/MGCLS or a related phenotype.20–22 Of note, these
reports identified different PTPN11 mutations (p.D106A,
p.F285L, p.N308S, p.A461T), which had previously been
observed to occur in subjects with NS or LS.20–22 Although
the relatively small number of cases analyzed so far does not
allow one to ascertain whether specific PTPN11 mutations
are preferentially associated with the development of
MGCL, the finding that the same changes found in NL/
MGCLS patients occur in NS patients without MGCL
indicates that the heterozygous condition for a PTPN11
mutation is not sufficient to produce these lesions. The
available genetic data support the view that NL/MGCLS,
similar to NS, is genetically heterogeneous,22 suggesting that
other genes coding for transducers participating in the RAS-
MAPK pathway might be involved in MGCL pathogenesis.
Herein, we report that syndromic MGCL may be caused
by mutations in various genes encoding other components
of the RAS-MAPK signaling cascade.
Patients and methods
The study population comprised a cohort of 75 patients
with a clinical diagnosis of NS, 4 of whom had MGCL. This
cohort included 49 NS cases originally studied by Musante
et al,23 as well as newly ascertained cases. All of them had
previously tested negative for PTPN11 and KRAS muta-
tions. The group of patients with syndromic MGCL was
completed by three individuals displaying MGCL asso-
ciated with a phenotype in keeping with or suggestive of
CFCS. The patients were screened for mutations in the
genes SOS1 and BRAF, MEK1 and MEK2, respectively.
The study was approved by the Review Boards of the
Universities of Erlangen and Berlin, and Children’s Hospi-
tal of Eastern Ontario, Ottawa. Written informed consent
was obtained from all patients or their legal guardians for
DNA analysis, publication of data, and for the photographs
presented here.
DNA extracted from blood cells was used for molecular
genetic testing. Mutational screening was carried out by
bidirectional direct sequencing using the BigDye Terminator
Sequencing Kit v2.1 (Applied Biosystems) and an automated
capillary sequencer (ABI 3730, Applied Biosystems) as
described previously.24 SOS1 screening was performed on
exons 3, 6–8, and 10–16, as these exons contain all
nucleotides reported previously to be mutated in patients
with NS.4,5,24 Similarly, BRAF mutation analysis was
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performed on exons 6 and exons 11–16, whereas screening
of the MEK1 and MEK2 genes was restricted to exons 2 and
3. SH3BP2 analyses were performed as published.16 Primer
pairs and PCR conditions are available on request.
Results
Mutations in the SOS1 gene were identified in 11 of the 75
index cases from the PTPN11 and KRAS mutation-negative
NS patient group, thus giving an SOS1 mutation frequency
of 14.7% in this cohort. All mutations had previously been
documented in NS.4,5,24 Among the NS patients tested
positive for an SOS1 mutation were the four individuals
with MGCL (Table 1). Molecular screening performed on
the additional three syndromic MGCL cases displaying a
phenotype fitting CFCS or suggestive of this condition
identified a heterozygous BRAF or MEK1 gene mutation in
all individuals (Table 1). All three mutations were de novo.
All of the three patients exhibited moderate-to-severe
cognitive defects, and two of them showed typical
ectodermal changes (Table 2). Taken together, all subjects
with a diagnosis of NS or CFCS with MGCL were found to
carry a mutated SOS1, BRAF, or MEK1 allele. All mutations
were missense and had previously been reported in subjects
with NS and CFCS, respectively, without apparent
MGCL.4,5,10,24,25
In all but one patient affected by MGCLs, the diagnosis
of NS/CFCS had been made clinically in infancy or
childhood before the appearance of disfiguring facial bone
involvement. In patient 4, who first came to medical
attention because of his mandibular tumescence, an initial
diagnosis of cherubism was made, whereas it was noticed
later that his additional features were compatible with NS.
Enlargement of the jaws was recognized at the age of 5–14
years in this cohort and has been slowly progressive in each
patient. In the three adult patients (patients 1, 4, and 5), T
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Table 1 SOS1, BRAF and MEK1 gene mutations detected
in the syndromic MGCL and NS cohorts
Disorder and
number of cases Gene
Nucleotide
change
Amino acid
change
NS with MGCL
1 SOS1 c.1297G4A p.E433K
1 SOS1 c.1656G4T p.R552S
2 SOS1 c.2536G4A p.E846K
CFCS with MGCL
2 BRAF c.770A4G p.Q257R
1 MEK1 c.389A4G p.Y130C
NS
1 SOS1 c.806T4G p.M269R
1 SOS1 c.1649T4C p.L550P
5a SOS1 c.1654A4G p.R552G
aIncluding one family transmitting the trait.
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GCLs have still been growing, in contrast to cherubism,
where a regression of GCLs is usually observed after
puberty.15 All patients except for patient 7 showed bilateral
involvement of the mandible. All patients had undergone
facial bone surgery and the typical histological appearance
of GCL was confirmed. Detailed clinical characterization
of these subjects is reported in Table 2. Among
them, patients 1, 4, and 5 exhibited the most severe bony
changes resembling the clinical picture of cherubism
(Figure 1a, c and e). Orthopantograms of patients 1 and 4
and histology photos of GCLs in patient 7 are shown in
Figure 2. SH3BP2 mutation analysis had been performed in
patients 1 and 4, and no mutation was identified.
Discussion
Noonan-like/MGCL syndrome was previously found to be
associated with PTPN11 mutations.20 – 22,26 This is the first
study that describes the association between MGCL and
mutations in other genes encoding components of the
RAS-MAPK pathway. The observed mutations are presumed
to lead to increased/dysregulated signaling.27 – 29 Taken
together, the findings in previous reports and the results of
this study suggest that various genetic alterations leading
to dysregulation of the RAS-MAPK pathway can contribute
to the development of MGCL. This is consistent with the
observation that MGCL are also a possible manifestation
of neurofibromatosis type 1 (NF1).30 – 33 NF1, the gene
mutated in NF1, encodes neurofibromin that acts as
a GTPase-activating protein (GAP) for RAS. Loss of GAP
activity leads to constitutive activation of RAS and
RAS-mediated signaling, which is functionally similar to
the presumed effect of activating mutations in PTPN11,
SOS1, BRAF, and MEK1.27 – 29
We also demonstrate for the first time that syndromic
MGCLS is not only associated with mutations that are
typical of NS or LS. The same bony lesions can be present in
patients who have clinical features consistent with or
suggestive of CFCS and are heterozygous for mutations in
genes known to be mutated in this developmental disorder
(cases 5–7; Table 2). Apart from the MGCL, the clinical
phenotype of these patients does not differ from that
Figure 1 Clinical features in patients with syndromic MGCLS. Severe involvement of the jaws resembling cherubism is present in patients 1 (a),
4 (c), and 5 (e). The second also shows severe scoliosis (c). Milder expression in patients 2 (b) and 7 (d). Development of the facial shape in patient 5
(e). (Patient are numbered according to Table 2.)
MGCLs in patients with NS and CFCS
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characterizing NS and CFCS patients without MGCL. These
findings emphasize that NL/MGCLS should no longer be
regarded as a separate entity. Instead, development of
MGCL should be considered as a rare but typical compli-
cation that may occur in patients with any of the disorders
having in common the dysregulation of RAS-MAPK
signaling. The incidence of MGCL in patients with NS or
CFCS is not known and has not been studied system-
atically. Whereas the unexpectedly high prevalence of
MGCL within the relatively small cohort of SOS1 mutation-
positive subjects with NS included in this study is most
likely due to chance, it is possible that single and small
lesions in the jaws might represent relatively common
events in these conditions, with only extensive growth and
multilocular occurrence most likely to be noticed clinic-
ally. We also consider the possibility that MGCL may occur
in patients with NS/CFCS and mutations in any of the
other known as well as in hitherto unknown genes. An
orthopantogram should be recommended in patients with
NS/CFCS and progressive facial coarsening.
Consequently, we postulate that dysregulation of the RAS-
MAPK pathway represents the common and basic molecular
event predisposing to MGCL formation in patients with NS,
LS, CFCS, and NF1. It is not clear whether specific mutations
are associated with an increased risk for MGCL develop-
ment, whereas others are not. Certain mutations have been
observed repeatedly in patients affected by NS/CFCS
with MGCL, such as PTPN11 mutations p.D106A and
p.F285L,4,5,22,26 the SOS1 mutation p.E846K, and the BRAF
mutation p.Q257R (this article), but the number of patients
with confirmed mutations is still too small to draw definite
conclusions. Of note, the same changes have been found
also in adult patients without apparent MGCL, indicating
that these mutations are not sufficient to produce the
tumor-like lesion. We therefore speculate that additional
factors (eg, modifier genes, epigenetic factors, or somatic
‘second hits’) contribute to the manifestation of MGCL in
patients with NS, LS, CFCS, or NF1. The observations of a
‘progressing phenotype’ in individual patients21 and of
multiple family members affected by an NS-like disorder but
being discordant for the presence of MGCL19 support this
hypothesis.
The association of MGCL with disorders of the
RAS-MAPK pathway further raises the speculation that
somatic mutations in components of this pathway might
play a role in the pathogenesis of nonsyndromic MGCL. It
was previously shown that a specific type of lymphopro-
liferative disorder, juvenile myelomonocytic leukemia
(JMML), is particularly related to mutations leading to
upregulated RAS-MAPK signaling, either as germline events
associated with NS or NF1 or as somatic mutations in
nonsyndromic cases.34,35 Likewise, MGCL might represent
another tumor-like lesion specifically linked to abnormal
RAS signaling. As osteoclasts originate from hematopoietic
cells similar to the myeloid precursors that underlie JMML,
a link between these different kinds of tumors seems
reasonable. Ueki et al36 have recently shown that myeloid
cells from mice expressing the cherubism-causing P416R
SH3BP2 mutant show increased responses to M-CSF and
RANKL stimulation and form macrophages and osteoclasts
through mechanisms that include increased ERK acti-
vation. Inappropriate ERK activation in these cells may
therefore represent the common pathogenetic mechanism
that underlies the development of MGCL.
In summary, we show that MGCL may occur in patients
with NS and CFCS with different underlying molecular
changes. We speculate that development of MGCL is
related to RAS-MAPK pathway dysregulation as the basic
underlying mechanism rather than specific mutation
effects. These aspects argue against the existence of an
NL/MGCLS as a separate entity. The findings of this study
should prompt molecular investigations in isolated GCL
and nonsyndromic MGCL.
Figure 2 (a) The radiographs of patients 1 and 4 show bilateral
extensive radiolucent lesions in the posterior mandible. (b) The
histology pictures of patient 7 show multinucleated giant cells within
a fibrous stroma. (HE stain, 100 and 400 original magnification.
Patients are numbered according to Table 2.)
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